Avastin bevacizumab regulatory update

Genentech reiterated its request to maintain accelerated approval for Avastin bevacizumab in combination with paclitaxel for HER2-negative metastatic breast cancer while the company conducts a

Read the full 259 word article

How to gain access

Continue reading with a
two-week free trial.